Want to see AU:BGT full AI Analyst Report?
BGT Stock Chart & Stats
AU$0.02
<AU$0.01(2.86%)
At close: 4:00 PM EDT
AU$0.02
<AU$0.01(2.86%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.05
Previous CloseN/A
Volume129.91K
Average Volume (3M)281.20K
Market Cap
AU$7.01M
Enterprise ValueAU$4.07
Total Cash (Recent Filing)AU$1.94M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Mar 03, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding438,061,100
10 Day Avg. Volume294,591
30 Day Avg. Volume281,196
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.81
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt reduces insolvency pressure and interest obligations, preserving financial flexibility while the company remains loss-making. This gives management more scope to fund operations, pursue development priorities, or raise capital without an already-heavy debt burden.
Reported EPS ImprovementReported positive EPS growth provides a limited indication that per-share performance has improved relative to the comparison period. If sustained, such improvement could support future earnings recovery, although it currently sits alongside persistent losses and near-zero revenue.
Losses StabilizedThe absence of a material further deterioration in losses offers a modest sign of operating stabilization. Holding losses broadly steady can preserve capital and create a base for recovery, though the business still needs meaningful revenue and profitability before this becomes a durable strength.
Bears Say
Near-Zero RevenueNear-zero revenue indicates that the company has not yet established a dependable commercial base capable of supporting ongoing operations. Without a sustained improvement in sales, fixed corporate costs and development spending are likely to remain difficult to cover through internally generated business activity.
Persistent UnprofitabilityRecurring operating and net losses demonstrate that the current business model has not yet reached a scalable, profitable state. Continued unprofitability limits internally funded investment, weakens resilience, and increases the importance of achieving a meaningful and sustained commercial turnaround.
Persistent Cash BurnOngoing negative operating cash flow shows that core activities are consuming rather than generating cash. Persistent cash burn can require repeated external funding, constrain investment choices, and leave the company more exposed if revenue recovery or financing access takes longer than expected.
Bio-Gene Technology Ltd. News
BGT FAQ
What was Bio-Gene Technology Ltd.’s price range in the past 12 months?
Bio-Gene Technology Ltd. lowest share price was AU$0.01 and its highest was AU$0.05 in the past 12 months.
What is Bio-Gene Technology Ltd.’s market cap?
Bio-Gene Technology Ltd.’s market cap is AU$7.01M.
When is Bio-Gene Technology Ltd.’s upcoming earnings report date?
Bio-Gene Technology Ltd.’s upcoming earnings report date is Mar 03, 2027 which is in 151 days.
How were Bio-Gene Technology Ltd.’s earnings last quarter?
Bio-Gene Technology Ltd. released its earnings results on Aug 28, 2026. The company reported -AU$0.003 earnings per share for the quarter.
Is Bio-Gene Technology Ltd. overvalued?
According to Wall Street analysts Bio-Gene Technology Ltd.’s price is currently Overvalued.
Does Bio-Gene Technology Ltd. pay dividends?
Bio-Gene Technology Ltd. does not currently pay dividends.
What is Bio-Gene Technology Ltd.’s EPS estimate?
Bio-Gene Technology Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio-Gene Technology Ltd. have?
Bio-Gene Technology Ltd. has 438,061,100 shares outstanding.
What happened to Bio-Gene Technology Ltd.’s price movement after its last earnings report?
Bio-Gene Technology Ltd. reported an EPS of -AU$0.003 in its last earnings report. Following the earnings report the stock price went up 5.556%.
Which hedge fund is a major shareholder of Bio-Gene Technology Ltd.?
Currently, no hedge funds are holding shares in AU:BGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bio-Gene Technology Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:BGT Sentiment 100%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth AU$20.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.94%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
21.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Technical Analysis
Biotron
―
Vectus Biosystems Limited
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―